KalVista Pharmaceuticals to Present New Sebetralstat Data at AAAAI/WAO 2025 Joint Congress
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage pharmaceutical company focused on developing oral therapies for rare diseases, has announced that six abstracts have been accepted for presentation at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress. This prestigious event will be held in San Diego, California, from February 28 to March 3, 2025. The conference serves as a key platform for researchers, clinicians, and industry leaders to discuss the latest advances in allergy, asthma, and immunology.
KalVista’s Presentations
KalVista will showcase new data on sebetralstat, an investigational oral therapy for hereditary angioedema (HAE), along with insights into the burden of injectable on-demand treatments and barriers to timely care. These findings highlight KalVista’s ongoing commitment to advancing therapeutic options for HAE patients, with a focus on efficacy, patient convenience, and improved disease management.
The company’s presentations are divided into three categories: poster presentations, late-breaking poster presentations, and an oral presentation. These sessions will provide valuable insights into hereditary angioedema treatment challenges, current therapeutic burdens, and promising results from KalVista’s investigational drug trials.
Poster Presentations – Friday, February 28, 2025
The first set of poster presentations will take place on Friday, February 28, 2025, from 2:45–3:45 pm PT in the Convention Center, Ground Level, Hall A. The presentations will cover critical issues faced by HAE patients, particularly those related to delays in treatment and barriers in different healthcare systems.
1. Barriers to Timely On-Demand Treatment of Hereditary Angioedema Attacks in Italian Patients (#180)
This study investigates the challenges that Italian HAE patients encounter when seeking timely on-demand treatment for acute attacks. Delays in receiving effective treatment can lead to severe health complications and reduced quality of life. The research team, led by Mauro Cancian and colleagues, analyzed various factors contributing to treatment delays, such as healthcare system limitations, patient access issues, and availability of medications. The findings aim to inform policy changes and optimize treatment strategies for HAE in Italy.
2. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Adolescents (#185)
This study, conducted by Mauro Cancian and an international team of researchers, evaluates the physical, emotional, and logistical burdens associated with injectable on-demand treatments for adolescent patients with HAE. Adolescents often face unique challenges when managing their condition, including difficulties with self-administration of injectable medications and anxiety related to treatment. The study underscores the need for alternative delivery methods that are more user-friendly and less distressing for younger patients.
3. Delays in the On-Demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported in Different Healthcare Systems (#187)
Led by Patrick Yong and a team of international researchers, this study examines how different healthcare systems contribute to delays in the treatment of HAE attacks. By comparing healthcare infrastructures across multiple regions, the study aims to identify systemic issues that hinder prompt treatment and propose solutions to improve patient outcomes. The findings emphasize the importance of streamlined access to on-demand therapies and increased awareness among healthcare providers.
Late-Breaking Poster Presentations – Saturday, March 1, 2025
The second set of presentations, classified as late-breaking posters, will take place on Saturday, March 1, 2025, from 9:45–10:45 am PT in the Convention Center, Ground Level, Hall A. These studies present new and emerging data related to hereditary angioedema diagnosis and treatment, including findings from KalVista’s ongoing clinical trials.
4. Study to Adjudicate Hereditary Angioedema with Normal C1INH Diagnoses in the PIONEER-HAE Database (#L14)
This study, led by Maeve O’Connor and colleagues, explores the diagnosis of hereditary angioedema in patients with normal C1 inhibitor (C1INH) levels. The research utilizes data from the PIONEER-HAE database to refine diagnostic criteria and ensure accurate identification of patients who may benefit from targeted therapies. The study’s findings are expected to contribute to more precise classification of HAE and improved patient care.
5. Effectiveness of Sebetralstat for the On-Demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S (#L15)
This interim analysis from the KONFIDENT-S trial, presented by Jonathan Bernstein and a team of international researchers, assesses the effectiveness of sebetralstat in treating laryngeal HAE attacks. Laryngeal attacks pose a severe risk due to potential airway obstruction, making rapid and reliable treatment essential. The findings suggest that sebetralstat may offer a promising new oral treatment option for managing these life-threatening episodes.
Oral Presentation – Saturday, March 1, 2025
In addition to the poster presentations, KalVista will deliver an oral presentation on Saturday, March 1, 2025, from 2:25–2:35 pm PT in the Convention Center, Room 6C, Upper Level. This session will focus on pooled data from two key clinical trials, KONFIDENT and KONFIDENT-S, providing a comprehensive analysis of sebetralstat’s efficacy in adolescent patients.
6. On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Adolescents: Pooled Analysis from KONFIDENT and KONFIDENT-S (#552)
Presented by Danny Cohn and a multidisciplinary team, this study compiles data from two major clinical trials to evaluate the safety and efficacy of sebetralstat in adolescent patients. The findings highlight the drug’s potential as a fast-acting, effective oral treatment that may reduce the need for injectable therapies. This presentation is expected to generate significant interest among healthcare professionals seeking improved treatment options for younger HAE patients.
Significance of KalVista’s Research
KalVista’s presentations at the AAAAI/WAO 2025 Joint Congress reflect the company’s dedication to addressing critical challenges in HAE treatment. By focusing on patient-centric solutions and developing innovative oral therapies like sebetralstat, KalVista aims to revolutionize the management of hereditary angioedema.
Sebetralstat’s potential as a non-injectable on-demand therapy represents a significant advancement in HAE care. If approved, it could provide patients with a more convenient and less invasive treatment option, improving adherence and quality of life. The data presented at this congress will further validate sebetralstat’s clinical benefits and support its continued development toward regulatory approval.
